Brentuximab vedotin treatment associated with acute and chronic inflammatory demyelinating polyradiculoneuropathies
- 23 April 2020
- journal article
- letter
- Published by BMJ in Journal of Neurology, Neurosurgery & Psychiatry
- Vol. 91 (7), 786-788
- https://doi.org/10.1136/jnnp-2020-323124
Abstract
Peripheral neuropathy is a frequent adverse event of BV treatment, affecting up to 60% to 70% of patients.1 It usually consists of a mild axonal, length-dependent, sensory neuropathy, characterised by numbness and tingling of fingers and toes,1 2 related to the toxic effect of monomethyl auristatin E on axonal microtubules.3 Nonetheless, immune-mediated peripheral neuropathies characterised by prominent motor impairment have also been described,4 suggesting that, similarly to other antineoplastic agents, BV might have the potential to induce or exacerbate inflammatory polyradiculoneuropathies. The aim of this study was to assess the characteristics of inflammatory demyelinating polyradiculoneuropathy associated with BV treatment.This publication has 5 references indexed in Scilit:
- Clinical and neurophysiological serial assessments of brentuximab vedotin-associated peripheral neuropathyLeukemia & Lymphoma, 2019
- Brentuximab vedotin or physician's choice in CD30-positive cutaneous T-cell lymphoma (ALCANZA): an international, open-label, randomised, phase 3, multicentre trialThe Lancet, 2017
- Brentuximab vedotin: axonal microtubule’s ApollyonBlood Cancer Journal, 2015
- Brentuximab vedotin as consolidation therapy after autologous stem-cell transplantation in patients with Hodgkin's lymphoma at risk of relapse or progression (AETHERA): a randomised, double-blind, placebo-controlled, phase 3 trialThe Lancet, 2015
- Severe peripheral motor neuropathy in a patient with Hodgkin lymphoma treated with brentuximab vedotinLeukemia & Lymphoma, 2013